Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study

Ajewole, Veronica B; Cox, James; Swan, Joshua T.; Chikermane, Soumya; Lamoth, Beverly; Iso, Tomona; Okolo, Laura O.; Ford, Christen L.; Schneider, Amy M.; Hobaugh, Eleanor C; Baker, Kelty R.

doi:10.1007/s00520-019-05006-6

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that the average CIPN–related QoL score of patients with advanced LC was 40.44 (SE = 0.57). The level of CIPN–related QoL among subjects in this study was lower than that reported in another recent study [ 39 ]. This difference may be due to the different cycles of chemotherapy during which patients were assessed.…”

Section: Discussioncontrasting

confidence: 92%

“…This difference may be due to the different cycles of chemotherapy during which patients were assessed. Patients in our study received an average of 5.53 cycles of chemotherapy and had not yet completed all cycles of chemotherapy, while patients in the study of Ajewole et al [ 39 ] were enrolled within two weeks of the first chemotherapy of cycle 1 and followed for 12 weeks after enrollment. These findings may reflect an increase over time of the impact of CIPN on QoL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Hung

Liu

Chen

et al. 2021

IJERPH

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL.

show abstract

Section: Discussioncontrasting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Hung

Liu

Chen

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…(SE = 0.57). The level of CIPN-related QoL among subjects in this study was lower than that reported in another recent study [34]. This difference may be due to the different cycles of chemotherapy during which patients were assessed.…”

Section: Discussioncontrasting

confidence: 87%

“…This difference may be due to the different cycles of chemotherapy during which patients were assessed. Patients in our study received an average of 5.53 cycles of chemotherapy and had not yet completed all cycles of chemotherapy, while patients in the study of Ajewole et al [34] were enrolled within 2 weeks of the rst chemotherapy of cycle 1 and followed for 12 weeks after enrollment. These ndings may re ect that the impact of CIPN on QoL increases over time.…”

Section: Discussionmentioning

confidence: 99%

Impact of Chemotherapy-induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-based Chemotherapy

Hung

Liu

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of cancer treatment that may affect quality of life (QoL). The purposes of this study were to: assess the levels of CIPN, depression, general QoL, and CIPN–related QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy.Methods: This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN, depression, general QoL, and CIPN-related QoL.Results: Of the 93 patients with advanced LC studied, 53.8% and 47.3% reported CIPN–sensory impairment and CIPN–motor impairment, respectively. The most common CIPN symptoms were difficulty getting or maintaining an erection and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL was associated with a higher level of depression, more CIPN-sensory impairment, and a higher cumulative dose of chemotherapy.Conclusion: More than half of LC patients report impairment related to CIPN. This finding highlights the importance of treating these symptoms which significantly impair QoL. A holistic approach — including patient health education, dietary adjustment, nutritional supplements, aerobic exercise, and balance training — is needed to relieve the distressful peripheral neurological symptoms and emotional distress of CIPN during and after treatment for advanced LC.

show abstract

“…The total score range is 0 to 44, with a high score signifying less neurotoxicity. The clinically significant development of CIPN was defined as a decrease in the FACT/GOG-Ntx score by > 10% between 2 consecutive time points [15,16]. The evaluations for CIPN symptoms were conducted for up to 6 chemotherapy cycles, and a further evaluation was made at 1 month after the course finished.…”

Section: Evaluation Criteria and Timingmentioning

confidence: 99%

Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trial

Chitkumarn

Rahong

Achariyapota

2022

Support Care Cancer

View full text Add to dashboard Cite

Objectives The primary objective of this study was to investigate the efficacy of cold therapy in reducing paclitaxel-based, chemotherapy-induced, peripheral neuropathy (CIPN). The secondary objective was to establish the incidence of CIPN arising from paclitaxel administration. Materials and methods The study enrolled gynecological cancer patients who were aged over 18 years and receiving chemotherapy which included paclitaxel (175 mg/m2 every 3 weeks). The patients were allocated to control and cold-therapy groups by computer randomization. During paclitaxel administration, frozen gloves developed in-house by Siriraj Hospital were worn—with a cold pack inside—on both hands and both feet by the cold-therapy patients. The CIPN incidence was evaluated by FACT/GOG-Ntx (version 4) at each chemotherapy cycle and at the 1-month follow-up after treatment completion. Results There were 79 patients (control arm, 40; study arm, 39). The CIPN incidences in the control and cold-therapy groups were 100% and 48.7%, respectively. CIPN was significantly decreased in the intervention group between the first cycle and the 1 month follow-up after chemotherapy cessation (P value < 0.001). Four patients discontinued the cold therapy due to pain, but there were no serious adverse effects due to the therapy. Conclusion The Siriraj Hospital, in-house-developed, frozen gloves can reduce CIPN effectively as part of cold therapy for paclitaxel-based chemotherapy. The benefits of using the gloves are apparent from the first chemotherapy cycle to the 1-month, post-treatment follow-up assessment.

show abstract

Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study

Cited by 9 publications

References 30 publications

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

Impact of Chemotherapy-induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-based Chemotherapy

Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trial

Contact Info

Product

Resources

About